AI Article Synopsis

  • People with HIV are at higher risk for health issues, and higher levels of interleukin 6 (IL-6) can predict these problems; tocilizumab (TCZ) is a drug that blocks IL-6's effects.
  • A 40-week study tested TCZ's safety and effectiveness on HIV patients already on antiretroviral therapy; participants alternated between TCZ and a placebo over different periods.
  • Results showed TCZ significantly reduced inflammation markers and was generally safe, although it did lead to some increases in lipid levels, which may pose cardiovascular risks and need further investigation.

Article Abstract

Background: People with human immunodeficiency virus (PWH) are at increased risk for comorbidities, and plasma interleukin 6 (IL-6) levels are among the most robust predictors of these outcomes. Tocilizumab (TCZ) blocks the receptor for IL-6, inhibiting functions of this cytokine.

Methods: This was a 40-week, placebo-controlled, crossover trial (NCT02049437) where PWH on stable antiretroviral therapy (ART) were randomized to receive 3 monthly doses of TCZ or matching placebo intravenously. Following a 10-week treatment period and a 12-week washout, participants were switched to the opposite treatment. The primary endpoints were safety and posttreatment levels of C-reactive protein (CRP) and CD4+ T-cell cycling. Secondary endpoints included changes in inflammatory indices and lipid levels.

Results: There were 9 treatment-related toxicities of grade 2 or greater during TCZ administration (mostly neutropenia) and 2 during placebo administration. Thirty-one of 34 participants completed the study and were included in a modified intent-to-treat analysis. TCZ reduced levels of CRP (median decrease, 1819.9 ng/mL, P < .0001; effect size, 0.87) and reduced inflammatory markers in PWH, including D-dimer, soluble CD14, and tumor necrosis factor receptors. T-cell cycling tended to decrease in all maturation subsets after TCZ administration, but was only significant among naive CD4 T cells. Lipid levels, including lipid classes that have been related to cardiovascular disease risk, increased during TCZ treatment.

Conclusions: TCZ is safe and decreases inflammation in PWH; IL-6 is a key driver of the inflammatory environment that predicts morbidity and mortality in ART-treated PWH. The clinical significance of lipid elevations during TCZ treatment requires further study. Clinical Trials Registration. NCT02049437.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371305PMC
http://dx.doi.org/10.1093/cid/ciad199DOI Listing

Publication Analysis

Top Keywords

human immunodeficiency
8
immunodeficiency virus
8
tcz
8
t-cell cycling
8
tcz administration
8
pwh
5
interleukin blockade
4
blockade tocilizumab
4
tocilizumab diminishes
4
diminishes indices
4

Similar Publications

Background: Activated Phosphoinositide 3-Kinase (PI3K) δ Syndrome (APDS), an inborn error of immunity due to upregulation of the PI3K pathway, leads to recurrent infections and immune dysregulation (lymphoproliferation and autoimmunity).

Methods: Clinical and genetic data of 28 APDS patients from 25 unrelated families were collected from fifteen Italian centers.

Results: Patients were genetically confirmed with APDS-1 (n = 20) or APDS-2 (n = 8), with pathogenic mutations in the PIK3CD or PIK3R1 genes.

View Article and Find Full Text PDF

Purpose: Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy, particularly dolutegravir. This study aimed to determine the prevalence and associated factors of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.

View Article and Find Full Text PDF

A thorough and precise comprehension understanding of the HIV epidemic is crucial for effective HIV prevention and control. This study aimed to update the estimates of the overall HIV burden in China in 2018 and to assess the trends of HIV prevalence, incidence, and mortality from 1985 to 2018. The Estimation and Projection Package (EPP)/Spectrum software was utilized for estimation, a method highly recommended by UNAIDS.

View Article and Find Full Text PDF

Background/objectives: As people with human immunodeficiency virus experience longer life expectancy, other causes of morbidity and mortality are being increasingly identified. The incidence of non-alcoholic fatty liver disease has recently been on the rise in Indonesia. People with human immunodeficiency virus on antiretroviral therapy are also at an increased risk of having non-alcoholic fatty liver disease.

View Article and Find Full Text PDF

Dr. Soumya Swaminathan, a renowned Indian physician and scientist, revolutionized medical practices through her significant contributions to tuberculosis and human immunodeficiency virus research, yielding a lasting impact on global health. As the former Chief Scientist of the World Health Organization, her committed approach to healthcare has been instrumental in linking scientific research and evidence to policy development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!